In Part 1 of this series, general wellness devices and mobile medical applications (MMAs) will be considered. Part 2 of this series will be devoted to clinical decision support (C
Digital health tools hold huge potential, and the evidence base is growing all the time – so what is holding us back and how does the sector overcome the multiple barriers to widespread ado
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.